Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection | Zendy

J. Stone Doggett | Zendy; Kayode K. Ojo | Zendy; Erkang Fan | Zendy; Dustin J. Maly | Zendy; Wesley C. Van Voorhis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection

Author(s) -

J. Stone Doggett,

Kayode K. Ojo,

Erkang Fan,

Dustin J. Maly,

Wesley C. Van Voorhis

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01823-13

Subject(s) - toxoplasma gondii , toxoplasmosis , kinase , apicomplexa , virology , in vivo , biology , microbiology and biotechnology , immunology , protozoal disease , antibody , biochemistry , malaria

Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research